Syreeta Latatia Tilghman

Pharmacy Building Room L149
Monday/Wednesday 3:00 PM - 4:30 PM
Thursday 2:00 PM - 3:00 PM

PHA 3567 Disease States I Tu. Th. 9:00AM - 10:40AM
PHA 3580L Human Structure and Function Lab Tu 11:00AM - 1:00PM
PHA 3581 Pathophysiology I Mon,Wed,Fri 11:30AM - 12:20PM
PHA 3910L Undergraduate Research Fr 4:00PM - 6:00PM
PHA 4019 Pharmaceutical Sciences III TuTh 2:30PM - 3:50PM
PHA 4019L Pharmaceutical Sciences III Skills Lab TuTh 4:00PM - 6:00PM
PHA 4510 General Pharmacology I Mon 11:05AM - 1:00PM
PHA 4510L General Pharmacology I Lab Fr 11:05AM - 1:00PM
PHA 7979 Advanced Research TuTh 12:00AM - 3:45AM

---

---

Dr. Syreeta L. Tilghman earned a Bachelor of Science in Chemistry from the University of Maryland Eastern Shore. She received a PhD in Pharmacology and Experimental Therapeutics from the University of Maryland, Baltimore where she was trained under Dr. Angela Brodie. Her predoctoral studies focused on demonstrating that upregulation of AIB1 (amplified in breast cancer-1), aromatase and estrogen receptor provide long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival. Upon completion of her doctoral studies, Dr. Tilghman conducted her post-doctoral studies with Drs. Matthew E. Burow and John A. McLachlan at Tulane University in the Center for Bioenvironmental Research in New Orleans, LA. As a postdoctoral fellow, she investigated mechanisms by which a novel plant derived antiestrogen, suppresses human breast tumorigenesis. In 2010 Dr. Tilghman joined Xavier University College of Pharmacy as an assistant professor of Pharmacology. In 2015, she joined Florida A&M University College of Pharmacy and Pharmaceutical Sciences as an associate professor and continued studying aromatase inhibitor resistance. She completed a cancer biology and therapeutics certification program from Harvard University Medical School in 2018. In 2021, she was invited to serve as standing member of the Molecular Cancer Therapeutics study section as a scientific reviewer to review NIH grant applications. She published numerous scientific articles in peer-reviewed journals. In 2023 she was promoted to full professor, and her research on aromatase inhibitor resistant breast cancer is currently funded through the NIH.

---

---

• Knitting
  

---

---

---

---

• Professor 2023-present
  Florida A&M University, Tallahassee, FL
• Adjunct Professor 2023-present
  University of Maryland Eastern Shore, Princess Anne, MD
• Associate Professor 2015-2023
  Florida A&M University, Tallahassee, FL
• Assistant Professor 2010-2015
  Xavier University of Louisiana, New Orleans, LA

---

---

•  Patel JR, Banjara B, Ohemeng A, Davidson, Boué S, Burow ME, Tilghman SL. Novel Therapeutic Combination Targets the Growth of Letrozole Resistant Breast Cancer Through Decreased Cyclin B1. Nutrients 2023, 15(7), 1632; https://doi.org/10.3390/nu15071632 (2023 impact factor: 6.706)
  
  
• Patel JR, Thangavelu P, Terrell RM, Israel B, Sarkar AB, Davidson AM, Zhang K, Khupse R, and Tilghman SL. A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells. Biomolecules. 2022 12(4), 531. https://doi.org/10.3390/biom12040531 (impact factor: 6.208)
  
  
• Walker RR, Patel JR, Gupta A, Davidson AM, Williams CC, Payton-Stewart F, Boué SM, Burow ME, Khupse R, and Tilghman SL. Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase Inhibitor Resistant Breast Cancer Cells through Induction of Apoptosis. Int J Mol Sci. 2022 Mar 7;23(5):2887.doi: 10.3390/ijms23052887. (impact factor: 6.208)
  
  
• Patel J, Gallegos KM, Walker RR, Davidson AM, Davenport IR, Tilghman SL. Mammary cancer stem cells promote an aggressive phenotype in letrozole resistant breast cancer. Oncology Letters. 2021 June 28; 620. DOI: 10.3892/ol.2021.12881(impact factor: 3.111)
  
  
• Gallegos KM, Patel JR, Llopis SD, Walker RR, Davidson AM, Zhang W, Zhang K, Tilghman SL. Quantitative Proteomic profiling identifies a potential novel chaperone marker in resistant breast cancer. Front Oncol. 2021 Feb 25;11:540134. doi: 10.3389/fonc.2021.540134. eCollection 2021.PMID: 33718123 (impact factor: 5.738)
  
  
• Walker RR, Gallegos KM, Bratton MR, Lemieux KP, Zhang K, Wang G, Davidson AM, Tilghman SL. Acquisition of Letrozole Resistance Through Activation of p38/MAPK Signaling Cascade. Anticancer Res. 2021 Feb;41(2):583-599. doi: 10.21873/anticanres.14810.PMID: 33517263 (2021 impact factor: 2.435)
  
  
• Gupta A, Gupta G, Mehta RR, Ivancic DZ, Walker RR#, Patel JR, Gallegos KM@, Davidson AM, Khan SA, Mehta RG, and Tilghman SL. A novel and cost-effective ex vivo orthotopic model for the study of human breast cancer in mouse mammary gland organ culture. Biol Open. 2020 May 29;9(5):bio051649. doi: 10.1242/bio.051649. PMID: 32366373 (2021 impact factor: 2.643)s

---

---

• 2021-present Standing Member of NIH Molecular Cancer Therapeutics B Study Section
  
• 2019-2020 FAMU Pharmaceutical Sciences Teacher of the Year
  
• 2018-2019 FAMU Emerging Researcher of the Year Award
  
• 2018-2019 Harvard Medical School Cancer Biology & Therapeutics: High-Impact Cancer Research Certification Program
  
• 2017 AACR Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Award
  
• 2014 Norman C. Francis Faculty Excellence Award for Excellence in Scholarship
  
• 2013 The Endocrine Society Outstanding Abstract Award
  
• 2012 Aromatase XI 11th International Aromatase Symposium Young Investigator Travel Award

---

---

•  Disease States I (PHA 3567) formerly Pathophysiology I (PHA 3581)
  
• Pharmaceutical Sciences III (PHA 4019)
  
• Pharmaceutical Sciences III Skills Lab (4019L)
  
• Graduate Research Seminar (PHA 6938)
  
• Graduate Pharmacology I (PHA 6513)
  
• Pharmaceutical Concepts (PHA 6517)
  
• Dissertation (PHA 7980)
  
• Advanced Research (PHA 7979)
  
• General Pharmacology (PHA 4510)
  
• General Pharmacology Lab (PHA 4510L)
  
• Disease Stated II (PHA 3568)
  
• Pharmaceutical Sciences II (PHA 3010)
  
• Pharmaceutical Sciences II Lab (PHA 3010L)
  
• Molecular Biotechnology (PHA 4574)
  
• The Basic Science of Oncology (PHA 6136)
  
• Endocrine Pharmacology (PHA 6547)
  
• Special Problems in Pharmaceutical Sciences (PHA 6907)